clearance – Page 17 – Communicable Diseases Research

Utilization of Airway Pressure Release Ventilation as a Rescue Strategy in COVID-19 Patients: A Retrospective Analysis

Original Research

Published on 2021-07-072022-10-29
Journal: Journal of Intensive Care Medicine [Category] COVID-19, MERS, SARS,

HLA-dependent heterogeneity and macrophage immunoproteasome activation during lung COVID-19 disease

폐 COVID-19 질병 중 HLA 의존적 이질성 및 대식세포 면역프로테아좀 활성화

Research

Published on 2021-07-052022-09-10
Journal: Journal of Translational Medicine [Category] SARS, 치료기술,

[키워드] A allele Activation addition allele alveolar alveolar clearance Analysis Antigen presentation Asian binding affinity bronchoalveolar caused CD68 Cell characterized clearance Cluster correlated COVID-19 COVID-19 disease COVID-19 patient COVID-19 patients COVID19 Defense disease effort ENCODE expression genomic heterogeneity HLA HLA-A Immunoproteasome impairment implication Integrative analysis less lung Macrophage macrophages mechanism MHC class MHC class I MHC class-I MHC-II mild case mild cases Peptidome populations positive positive relationship predict proteome PSMB8 Result SARS-CoV-2 SARS-CoV-2 RNA SARS-CoV-2 vaccine SARS-CoV-2 virus severe COVID-19 Single Cell single-cell transcriptome single-cell transcriptomes supplementary material Symptom the binding affinity the disease the SARS-CoV-2 the SARS-CoV-2 virus these cell These cells tissue trajectory Transcriptome transcriptomes widespread worldwide pandemic
[DOI] 10.1186/s12967-021-02965-5 PMC 바로가기 [Article Type] Research

Increased susceptibility of human endothelial cells to infections by SARS-CoV-2 variants

Original Contribution

Published on 2021-07-052022-10-28
Journal: Basic Research in Cardiology [Category] COVID-19, Fulltext,

[키워드] ACE2 angiotensin-converting enzyme 2 B.1.1.7 B.1.351 caused Cell cellular distribution clearance Coronavirus disease 2019 COVID-19 direct infection double-stranded EDEM1 Effect Effects elevated endothelial Endothelial cell endothelial cells Endothelial dysfunction ER stress expressed Health higher risk highest Human in vitro Increased induce Infection Infectious virus Inflammation inoculated lung marker misfolded protein Mortality novel coronavirus SARS-CoV-2 P.2 Patient pro-inflammatory promote receptor reduced required responsible SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant significantly higher Spike protein supernatant supplementary material susceptibility susceptible tested the SARS-CoV-2 the spike protein umbilical variant vascular bed Viral RNA viral spike protein virus infection virus replication Virus trapping wild type
[DOI] 10.1007/s00395-021-00882-8 PMC 바로가기 [Article Type] Original Contribution

Safety and Efficacy of Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19 Population

COVID-19 인구에서 레닌-안지오텐신-알도스테론계 억제제의 안전성 및 효능

Meta-Analysis

Published on 2021-07-012022-09-11
Journal: High blood pressure & cardiovascular prevention : [Category] SARS, 임상,

[키워드] 95% CI ACEi age aldosterone Analysis angiotensin angiotensin receptor blocker angiotensin-converting enzyme inhibitor antibodies ARB association clearance clinical manifestation clinical manifestations Comorbidities contraindication converting enzyme inhibitor COVID-19 COVID-19 patient database Digital enzyme Enzyme inhibitor group higher odd higher odds ICU admission inhibitor inhibitors intensive care units males Mortality negative RT-PCR observational studies observational study Odds ratio outcome outcomes pandemic Population Primary outcome progression RAASi receptor receptor blocker Renin renin-angiotensin-aldosterone system Renin–angiotensin–aldosterone system inhibitors. RT-PCR Safety secondary outcome Seropositivity Sex Symptoms System viral clearance was used worsening
[DOI] 10.1007/s40292-021-00462-w PMC 바로가기 [Article Type] Meta-Analysis

Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19

COVID-19 입원 환자에서 하이드록시클로로퀸의 약동학 및 약력학

Observational Study

Published on 2021-07-012022-09-11
Journal: Thérapie [Category] SARS, 임상, 치료기술,

[키워드] 95% confidence interval Administered Analysis Bioavailability C-reactive protein circulating clearance Concentration covariates COVID-19 COVID-19 patient COVID-19 patients daily dose distribution dosage dose e parameters effective elimination half-life estimate followed by half-life HCQ hospitalized patient hospitalized patients Hydroxychloroquine in vitro Inflammation inhibit intensive care units Liquid chromatography Loading doses Lupus median nasopharyngeal swabs Non-COVID-19 patients parameter Patient performed Pharmacodynamics pharmacokinetic pharmacokinetic analysis pharmacokinetic data pharmacokinetics plasma plasma concentration ranged reported required reverse transcription-PCR SARS-CoV-2 SARS-CoV-2 viral severe COVID-19 patient severe COVID-19 patients tested Variability viral clearance Volume volume of distribution were measured with COVID-19
[DOI] 10.1016/j.therap.2021.01.056 PMC 바로가기 [Article Type] Observational Study

COVID-19 versus Non-COVID-19 Acute Respiratory Distress Syndrome: Comparison of Demographics, Physiologic Parameters, Inflammatory Biomarkers, and Clinical Outcomes

COVID-19 대 비-COVID-19 급성 호흡 곤란 증후군: 인구 통계, 생리학적 매개변수, 염증성 바이오마커 및 임상 결과의 비교

Observational Study

Published on 2021-07-012022-09-11
Journal: Annals of the American Thoracic Society [Category] SARS, 바이오마커, 임상, 치료기술,

[키워드] acute respiratory distress acute respiratory distress syndrome adjusted analyses analyzed ARDS Bacterial Biomarkers black body mass body mass index carbon dioxide clearance clinical Clinical characteristics Clinical outcome clinical outcomes Clinical research cohort of patient collected comparison conducted coronavirus disease COVID-19 Cox proportional hazard Culture detectable deviation enrolled etiology groups hypoxemic IL-10 IL-6 IL-6 level IL-8 intubation Kaplan-Meier Lung injury management mechanical ventilation mechanism minute ventilation Mortality no difference no differences Non-COVID-19 nonparametric test Nonparametric tests Observational cohort study on mechanical ventilation outcome outcomes parameters Patient patients with COVID-19 Peripheral blood Physiologic plasma Pneumonia proportional hazards models rationale recorded Research respiratory respiratory distress Respiratory distress syndrome SARS-CoV-2 secondary to similarity Skilled nursing facilities specimen static compliance syndrome systemic level treat Viral with COVID-19
[DOI] 10.1513/AnnalsATS.202008-1026OC PMC 바로가기 [Article Type] Observational Study

A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial

Clinical Trial

Published on 2021-07-012022-10-05
Journal: International immunopharmacology [Category] SARS, 바이오마커, 임상, 치료법, 치료제,

[키워드] Administered administration adverse event Anti-inflammatory antioxidant Antiviral average bilateral interstitial infiltrate Biomarker change clearance clinical clinical symptom Clinical symptoms clinical trial conducted coronavirus COVID-19 COVID-19 patient Day discharge discharged effective Efficacy evaluate IL6 IMPROVE intravenous laboratory biomarkers LDH Mild moderate not significant oxygen supplementation Oxygenation Ozonised saline Patient patients with moderate pilot clinical trial pilot study Pneumonia prevent disease progression radiological finding recorded recruitment reduced reduction required resolved Safe saline intravenously SARS-CoV-2 SpO2/FiO2 statistically statistically significant Symptom the disease therapeutic therapeutic potential therapy Treatment was done X-ray
[DOI] 10.1016/j.intimp.2021.107743 PMC 바로가기 [Article Type] Clinical Trial

Stress among Resident Doctors Working in Different Hospitals of Nepal in the Face of COVID-19 Pandemic: A Descriptive Cross-sectional Study

Original Article

Published on 2021-06-302022-10-30
Journal: JNMA: Journal of the Nepal Medical Association [Category] COVID-19, SARS,

Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial

Research Paper

Published on 2021-06-272022-10-04
Journal: EClinicalMedicine [Category] 신약개발, 임상,

[키워드] 1:1 95% CI 95% confidence interval accelerate Adverse adverse events assigned baseline clearance Cohort collected conducted COVID-19 COVID-related symptoms cycle threshold develop died drug discontinuation early treatment Effect emtricitabine Endpoint enrolled enrolment event finding France fumarate funding gastrointestinal side effect hospital hospitalisation in both groups Inclusion increase in Infection interfere IQR less median nasopharyngeal Nasopharyngeal swab Open-label Other Outpatient Patient per day phase 2 trial pilot study Randomized Randomly RdRP receive Registered reported RNA polymerase RT-PCR SARS CoV-2 SARS-COV-2 infection SARS-CoV-2 viral SARS-CoV-2 viral load secondary endpoint severe COVID-19 Standard of care Support symptom onset tenofovir therapy Time to recovery treated treatment group Trial viral burden
[DOI] 10.1016/j.eclinm.2021.100993 PMC 바로가기 [Article Type] Research Paper

Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail

regen-cov 항-스파이크 모노클로 날 항체 칵테일에 의한 B- 세포 고갈 관련 장기 (B-DEAP) covid에서 300 일 SARS-COV-2 감염의 성공적인 허가

Case Reports

Published on 2021-06-232022-09-01
Journal: Viruses [Category] MERS, SARS, 진단,

[키워드] anti-CD20 anti-CD20-mediated B-cell depletion anti-COVID-19 vaccine anti-SARS-CoV-2 vaccination anti-spike monoclonal antibodies anti-spike monoclonal antibody B-cell B-cell depletion associated prolonged COVID-19 B-DEAP COVID-19 Care Chemotherapy clearance Clinical course clinical decision cocktail consolidation coordination COVID COVID-19 COVID-19 infection current Day Depletion develop Diagnosis disappearance dose failure FDA first dose follicular Follicular lymphoma Health Health care Hospitalized Humoral immunity immunology Infection infused infusion initial input IRB lymphoma male management Mild monoclonal antibodies monoclonal antibody mutations obinutuzumab Patient persistence Pfizer-BioNTech Pharmacology Prolonged quarantine REGEN-COV REGN10933 and REGN10987 required SARS-CoV-2 SARS-CoV-2 persistence SARS-CoV-2 virus spike mutation the patient therapeutic option therapy treated vaccination Virology virus clearance virus mutations was performed
[DOI] 10.3390/v13071202 PMC 바로가기 [Article Type] Case Reports